Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement

Dec

09

Today In Oncology

One in Three Families of Children With ALL Face Financial Hardship During Treatment

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL

Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL

New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML

Advertisement

© 2025 HSP News Service, L.L.C.